OneSource Specialty Pharma: A capacity-led bet on the GLP-1 gold rush
Published on: May 9, 2026, 7:30 a.m. | Source: The Indian Express
OneSource Specialty Pharma is scaling its GLP-1 manufacturing business as semaglutide patent expiries and rising global demand create major CDMO opportunities.
